Advanced Cell Technology, Inc., (“ACT” OTCBB: ACTC)s a biotechnology company that specializes in the development of cellular therapies for the treatment of diseases and conditions that impact tens of millions of people worldwide. The company applies stem cell-based technologies (both for adult and "embryo-safe" human embryonic stem cells) and other proprietary methods in the field of regenerative medicine to bring patient-specific therapies from the lab bench to the bedside.
ACT's principal laboratory, GMP facility and corporate offices are in Marlborough, Massachusetts. ACT is led by an experienced management team and a world-class scientific team helmed, respectively, by Interim President, CFO and Executive Vice President of Corporate Development Ted Myles and Chief Scientific Officer Robert Lanza, M.D.
ACT has three cellular product platforms based on ground-breaking stem cell technology. As documented in the journals Nature and Cell Stem Cell, ACT developed and holds in its repertoire the first-ever proven alternative method for successful hESC generation without harm to the embryo, called the "single-cell blastomere" technique, on which it holds broad intellectual property (IP) protection. Early results from the first patients treated in ongoing clinical trials of the hESC-based treatment were published in The Lancet.